Century Therapeutics Inc (IPSC) - Total Assets
Based on the latest financial reports, Century Therapeutics Inc (IPSC) holds total assets worth $287.01 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Century Therapeutics Inc - Total Assets Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see IPSC market cap overview for the company's overall valuation and market capitalisation.
Century Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Century Therapeutics Inc's total assets of $287.01 Million consist of 54.0% current assets and 46.0% non-current assets. Review debt load of Century Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.7% |
| Accounts Receivable | $667.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $34.20 Million | 15.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Century Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Century Therapeutics Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Century Therapeutics Inc's current assets represent 54.0% of total assets in 2025, an increase from 0.0% in 2015.
- Cash Position: Cash and equivalents constituted 27.7% of total assets in 2025, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 4.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 15.3% of total assets.
Century Therapeutics Inc Competitors by Total Assets
Key competitors of Century Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Century Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.28 | 10.72 | 15.12 |
| Quick Ratio | 8.28 | 10.72 | 15.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $109.70 Million | $145.22 Million | $280.53 Million |
Century Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Century Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 1.51 |
| Asset Growth Rate (YoY) | -36.7% |
| Total Assets | $223.70 Million |
| Market Capitalization | $336.80 Million USD |
Valuation Analysis
Above Book Valuation: The market values Century Therapeutics Inc's assets above their book value (1.51x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Century Therapeutics Inc's assets decreased by 36.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Century Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Century Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $223.70 Million | -36.67% |
| 2024-12-31 | $353.22 Million | -2.07% |
| 2023-12-31 | $360.69 Million | -25.87% |
| 2022-12-31 | $486.54 Million | +11.24% |
| 2021-12-31 | $437.38 Million | +309.62% |
| 2020-12-31 | $106.78 Million | +17.47% |
| 2019-12-31 | $90.90 Million | -88.01% |
| 2016-12-31 | $758.00 Million | -10.26% |
| 2015-12-31 | $844.70 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more